Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1
Mumbai: Suven Pharmaceuticals Limited, a contract development and manufacturing organization (CDMO), has announced that
it has received final approval from the Department of Pharmaceuticals (DoP),
Ministry of Chemicals and Fertilizers, Government of India, for foreign investment
under applicable regulations.
This marks the final regulatory clearance required to
implement the Scheme of Amalgamation between Cohance Lifesciences Limited
and Suven Pharmaceuticals Limited, a transaction previously approved by
shareholders and sanctioned by the Hon’ble NCLT, Mumbai Bench.
In line with the terms of the approved Scheme of Amalgamation, the merger will
take effect from the business opening hours of 1st May 2025, following the
satisfaction of all prescribed conditions.
The merged company will operate under the name Cohance Lifesciences Limited,
subject to applicable regulatory approvals, reflecting a unified platform with
expanded CDMO capabilities.
“This approval is a significant milestone and reinforces the strategic vision behind
the merger,” said Vivek Sharma, Executive Chairman, Suven Pharmaceuticals. “We
are combining niche, technology-led capabilities to create a differentiated,
innovation-driven global CDMO. This integration positions us to scale complex
modalities such as ADCs and Oligonucleotides, deepen customer partnerships,
and enhance execution across the value chain—enabling us to deliver on our US$1
billion(INR85bn) revenue ambition through a mix of organic growth and strategic
acquisitions.”
“The merged entity will operate with an expanded scope of capabilities across the
pharmaceutical value chain, combining Suven’s scale and commercial execution
strengths with Cohance’s domain expertise in Antibody-Drug Conjugates (ADCs)
and complex chemistry platforms. This integration strengthens our positioning as an innovation driven integrated CDMO partner to global innovators, with a focus on
scaling high-growth modalities such as ADCs and oligonucleotides,” Suven Pharma stated.
The Board has also approved Thursday, May 8, 2025, as the Record Date for
determining the eligible shareholders of Cohance Lifesciences Limited who shall
receive equity shares of Suven Pharmaceuticals as per the approved share
exchange ratio under the Scheme of Amalgamation.
With the merger becoming effective, the Company has initiated the operational
and organizational integration, aligning systems, capabilities, and teams.